Literature DB >> 21527930

High-content screening: getting more from less.

J Philip McCoy.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21527930      PMCID： PMC3519355          DOI： 10.1038/nmeth.1599

Source DB:  PubMed          Journal:  Nat Methods        ISSN： 1548-7091            Impact factor:   28.547


× No keyword cloud information.
  6 in total

Review 1.  High content screening: seeing is believing.

Authors:  Fabian Zanella; James B Lorens; Wolfgang Link
Journal:  Trends Biotechnol       Date:  2010-03-24       Impact factor: 19.536

2.  Multiplex analysis of inflammatory signaling pathways using a high-content imaging system.

Authors:  Malene Bertelsen
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

3.  A yeast-based model of alpha-synucleinopathy identifies compounds with therapeutic potential.

Authors:  Gerard Griffioen; Hein Duhamel; Nele Van Damme; Klaartje Pellens; Piotr Zabrocki; Christophe Pannecouque; Fred van Leuven; Joris Winderickx; Stefaan Wera
Journal:  Biochim Biophys Acta       Date:  2005-12-27

Review 4.  Image analysis in high-content screening.

Authors:  Antje Niederlein; Felix Meyenhofer; Daniel White; Marc Bickle
Journal:  Comb Chem High Throughput Screen       Date:  2009-11       Impact factor: 1.339

Review 5.  Moving pictures: imaging flow cytometry for drug development.

Authors:  Gary S Elliott
Journal:  Comb Chem High Throughput Screen       Date:  2009-11       Impact factor: 1.339

6.  A parallel microfluidic flow cytometer for high-content screening.

Authors:  Brian K McKenna; James G Evans; Man Ching Cheung; Daniel J Ehrlich
Journal:  Nat Methods       Date:  2011-04-10       Impact factor: 28.547
  6 in total
  3 in total

1.  In vivo high-content evaluation of three-dimensional scaffolds biocompatibility.

Authors:  Mariana B Oliveira; Maximiano P Ribeiro; Sónia P Miguel; Ana I Neto; Paula Coutinho; Ilídio J Correia; João F Mano
Journal:  Tissue Eng Part C Methods       Date:  2014-03-31       Impact factor: 3.056

2.  Evolution of biologics screening technologies.

Authors:  Peter Cariuk; Matthew J Gardener; Tristan J Vaughan
Journal:  Pharmaceuticals (Basel)       Date:  2013-05-14

3.  Metabolic remodeling by TIGAR overexpression is a therapeutic target in esophageal squamous-cell carcinoma.

Authors:  Jiahui Chu; Xiangjie Niu; Jiang Chang; Mingming Shao; Linna Peng; Yiyi Xi; Ai Lin; Chengcheng Wang; Qionghua Cui; Yingying Luo; Wenyi Fan; Yamei Chen; Yanxia Sun; Wenjia Guo; Wen Tan; Dongxin Lin; Chen Wu
Journal:  Theranostics       Date:  2020-02-10       Impact factor: 11.556
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.